- Aytu BioScience press release ( NASDAQ: AYTU ): Q2 GAAP EPS of -$2.15.
- Revenue of $26.28M (+13.6% Y/Y).
- Net revenue from the Company's Rx segment was $18.0 million during Q2 2023 compared to $14.6 million in the year ago quarter, growth of 23%.
- ADHD products (Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue increased by 2% to $11.1 million from $10.9 million in the year ago quarter.
- Pediatric products (Poly-Vi-Flor®, Tri-Vi-Flor®, and Karbinal® ER) net revenue increased 95% to $6.3 million, from $3.2 million in the year ago quarter.
- Consumer Health revenue during Q2 2023 was $8.3 million
For further details see:
Aytu BioScience GAAP EPS of -$2.15, revenue of $26.28M